| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8453771 | Lung Cancer | 2018 | 6 Pages |
Abstract
KRAS mutational status can affect the immune microenvironment and survival of LADC patients in a heterogeneous way, implying that specific mutant KRAS variants expressed by the tumor should be considered when stratifying patients for immunotherapy.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Alexander T. Falk, Nathalie Yazbeck, Nicolas Guibert, Emmanuel Chamorey, Agnès Paquet, Lydia Ribeyre, Coraline Bence, Katia Zahaf, Sylvie Leroy, Charles-Hugo Marquette, Charlotte Cohen, Baharia Mograbi, Julien Mazières, Véronique Hofman,